We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA rejected Genta’s new drug application (NDA) for Genasense plus chemotherapy in patients with chronic lymphomatic leukemia (CLL), the company announced.